DarbeLus
A Phase II Study of Luspatercept Plus Darbepoetin Alfa in Non-mutated SF3B1 Lower-risk Myelodysplastic Syndromes
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 60 patients (estimated)
- Sponsors
- Smilow Cancer Hospital at Yale New Haven
- Collaborators
- Bristol Myers Squibb
- Tags
- Red Blood Cell Stimulant
- Trial Type
- Supportive
- Last Update
- SparkCures ID
- 2163
- NCT Identifier
- NCT07096297
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.